AzTrials
AzTrials

StrokeNCT04178395

Early Neurophysiological Interventions in Acute Cerebral Lesions

A study testing bihemispheric transcranial direct stimulation in people with Stroke and Acute Stroke, run by Sara Yagüe MD at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: Transcranial direct current stimulation (tDCS) can change the excitability of the central nervous system and contribute to motor recovery of stroke patients. The investigators hypothesized that the benefit of tDCS may increase with interventions facilitating motor responses, such as repetitive peripheral… Read more about this study

Who is it for?
Ages 18 to 79 years
Conditions the study is for
Stroke, Acute Stroke
What is being tested?
bihemispheric transcranial direct stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
1 siteSpain
Study dates
8 Apr 2011to 9 Nov 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 79 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • first time single and unilateral supratentorial stroke confirmed by CT or MRI.
  • stroke interval between 5 and 20 days of study onset.
  • age 18 to 79 years,
  • National Institutes of Health Stroke Scale (NIHSS) ≥6 and ≤21.

Who cannot join

  • preceding epileptic seizures.
  • metallic implants within the brain or pacemaker implants.
  • coexistence of other neurological diseases

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Bellvitge University Hospital

    Barcelona, 08907

Other trials in Spain

About this study

Objective:

Transcranial direct current stimulation (tDCS) can change the excitability of the central nervous system and contribute to motor recovery of stroke patients. The investigators hypothesized that the benefit of tDCS may increase with interventions facilitating motor responses, such as repetitive peripheral nerve stimulation (rPNS).

Read more

The aim of our study was to examine the short and long-term effects of real vs sham bihemispheric tDCS on scales of motor function and neurophysiological tests in patients with acute stroke and a moderate/severe motor impairment.

Methods:

The study was prospective, randomized, double-blind and placebo controlled. Twenty acute stroke patients (ischemic and haemorrhagic) with Upper limb Fugl-Meyer (ULFM) score<19 were randomized in two parallel groups: one group received 5 consecutive daily sessions of anodal tDCS over the affected hemisphere (AH) and cathodal over unaffected hemisphere combined with rPNS and the other received sham tDCS associated to rPNS. Pacients were examined before tDCS, 5 days and 3, 6 and 12 months after tDCS. The investigators evaluated ULFM and modified Ashworth scales (MAS), resting motor threshold, motor and somatosensory evoked potentials (MEPs and SEPs), silent periods and Hmax/Mmax ratio.

Read the detailed description

Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation used to induce excitability changes in central nervous system circuits. The basis of tDCS application in stroke patients follows the model of interhemispheric imbalance between the damaged and intact hemispheres: anodal tDCS over affected hemisphere to induce long-lasting increase in cortical excitability, cathodal tDCS over unaffected hemisphere to induce long-lasting decrease in cortical excitability. Simultaneous effects on both hemispheres can be obtained with bi-hemispheric tDCS. Minimum intensity and duration of tDCS is necessary to induce long-lasting effects, which are referred as long-term potentiation and long-term depression.

Most interventional tDCS studies have focused on chronic stroke patients, at a time in which patients are supposed to have reached a plateau in their spontaneous recovery after the lesion. Less research has evaluated the effects of an early tDCS intervention. tDCS protocols differ in location of electrodes, session frequency and duration, dosage of electrical charge, temporal window of tDCS delivery and other variables. The functional benefit of tDCS may increase with the concomitant application of adjuvant therapeutic strategies such as constraint-induced therapy, electrical stimulation or robot-mediated therapy. Sattler et al. used radial nerve stimulation, together with tDCS, to facilitate motor output. It is possible that repetitive peripheral nerve stimulation (rPNS) modulates corticospinal output at somatotopically specific supraspinal sites through GABAergic interneurons. The patients that improved in Sattler et al.'s study, as in other tDCS studies, had an initial mild to moderate impairment of motor function. Improvement is more dubious in patients presenting with severe motor deficit.

Our aim in this study was to examine the effectiveness of bihemispheric tDCS combined with rPNS in acute stroke patients with pronounced motor impairment, the group of patients with fewer options in therapeutic programs.

The benefit of applying tDCS early after stroke is still unclear. However, based on animal models, the first month after stroke seems to be the optimal period to induce morphological changes associated with increased plasticity, hence the therapeutic window was chosen between 5 and 20 days after the stroke event. The investigators reasoned that, if plastic changes have been induced by tDCS, the clinical and neurophysiological benefit may manifest not just immediately after treatment, but further ahead in the patient's natural evolution after the stroke. For this reason, the investigators considered relevant to determine if the results of tDCS treatment persisted in time and had a long-term effect, therefore extended our clinical and neurophysiological follow-up to 12 months after treatment.

Methods:

Patients:

Twenty patients with a history of first acute stroke (ischemic and haemorrhagic) were included, from April through December 2011, in a prospective, double-blind, randomized study. Eleven patients were affected by an ischemic stroke: cortical and/or subcortical and 9 were affected by a haemorrhagic stroke. Inclusion criteria were: first time single and unilateral supratentorial stroke confirmed by CT or MRI, stroke interval between 5 and 20 days of study onset, age 18 to 79 years, National Institutes of Health Stroke Scale (NIHSS) ≥6 and ≤21. Exclusion criteria were preceding epileptic seizures, metallic implants within the brain or pacemaker implants and coexistence of other neurological diseases.

Patients were included in the study when they were medically stable, between 5 and 17 days after the stroke event. The study was conducted in according to the World Medical Association Declaration of Helsinki and approved by the Clinical Research Ethics Committee (PR160/11). Written, informed consent was obtained from all participants or their relatives before their inclusion in the study.

Patients were randomized in two parallel groups: one group (11 patients) received 5 consecutive daily sessions of anodal tDCS over the affected hemisphere and cathodal over unaffected hemisphere combined with repetitive peripheral nerve stimulation and the other (9 patients) received sham tDCS associated to repetitive peripheral nerve stimulation.

Patients were examined before tDCS, 5 days and 3, 6 and 12 months after tDCS.

Assessments Patients' condition was characterized using standardized clinical and neurophysiological assessment tools on the day before onset of interventions.

Clinical assessment Neurological functioning was assessed using the NIHSS. Motor assessment of the paretic upper limb and spasticity were evaluated using the upper limb Fugl-Meyer (ULFM) and Modified Ashworth scales (MAS). MAS scale measures were taken for shoulder abduction, elbow extension and wrist extension, which were used to calculate the mean value of resistance during passive stretching, with higher scores reflecting greater resistance (maximum 4).

Neurophysiological assessment

Transcranial magnetic stimulation:

Motor evoked potentials (MEPs) were recorded using a biphasic magnetic stimulator (Magstim 200; The Magstim Co. Ltd., UK) connected to a figure-of-eight magnetic stimulating coil (70-mm outer diameter; The Magstim Co. Ltd., UK) placed over the cortical abductor digiti minimi hotspot. A tight-fitting cloth cap marked with a 1cmx1cm grid was used for the mapping of the target muscle cortical representation. The coil was positioned tangentially to the scalp, with the handle pointing backwards at an angle of 45 degrees to midline and was moved in 1-cm steps to localize the optimal scalp location in each hemisphere, from which the largest MEPs in the abductor digiti minimi could be evoked. A Synergy electromyograph (Oxford Instruments, Surrey, UK) was used to record MEPs from the abductor digiti minimi. Whenever MEPs were not elicited in the affected upper limb at rest using maximal stimulator output, patients were instructed to make an attempt to voluntarily activate the muscle. If no MEP could be elicited using maximal stimulator output, MEPs amplitude was described as 0 mV.

Groppa S, Oliviero A, Eisen A et al. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2012;123:858-882.

Resting motor threshold:

Resting motor threshold (rMT) was defined as the lowest stimulator output at the optimal scalp site required to elicit a MEP of at least 50 μV in the relaxed abductor digiti minimi in at least 5 of 10 trials.21 If no MEP could be elicited using maximal stimulator output, then rMT was described as 100%.

Contralateral and ipsilateral silent period:

To elicit the silent period, transcranial magnetic stimulation was applied over the M1 area of each hemisphere while patients sustained a steady maximum tonic contraction of the abductor digiti minimi and a 500ms poststimulus period was analysed. Stimulation intensity was 120% rMT. We essentially recorded simultaneously contralateral (cSP) and ipsilateral silent period (iSP) to a unilateral stimulus. If patients were unable to maintain a stable contraction with the paretic hand, the SP was considered unmeasurable. cSP duration was measured from the onset of the MEP to the point of EMG resumption after a period of EMG suppression and the mean of 10 trials was used to estimate the silent period duration. iSP was quantified considering a period of relative suppression of EMG activity below the background EMG activity.

Takechi U, Matsunaga K, Nakanishi R et al. Longitudinal changes of motor cortical excitability and transcallosal inhibition after subcortical stroke. Clin Neurophysiol 2014;125: 2055-2069.

SEPs recording:

Somatosensory evoked potentials (SEPs) were elicited using electrical stimulation with the same procedure described in detail in previous studies. Signals were recorded using Synergy electromyograph (Oxford Instruments, Surrey, UK). SEPs data were compared between affected and unaffected upper limbs.

Cruccu G, Aminoff MJ, Curio G et al. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 2008;119:1705-19.

Mauguière F, Allison T, Babiloni C et al. Somatosensory evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999;52:79-90.

H-reflex H-reflex responses were recorded from a 45-degree angle supinated arm and a slightly contracted flexor carpi radialis muscle. When the flexor carpi radialis muscle couldn't be contracted the paretic upper limb was positioned with the wrist in slight flexion. Recording electrode was placed over the belly of the flexor carpi radialis and referred to an electrode 3 cm distal. Electrical stimuli delivered a square-wave pulse of 0.5 ms in duration and were applied over the median nerve at the bicipital groove; above the cubital crease. Hmax/Mmax responses were compared between the paretic and non-paretic sides.

Christie AD, Inglis JG, Boucher JP, Gabriel DA. Reliability of the FCR H-reflex. J Clin Neurophysiol 2005;22:204-9.

Conditions
Stroke, Acute Stroke
Being tested
bihemispheric transcranial direct stimulation
Keywords
transcranial direct current stimulation, stroke rehabilitation, neuromodulation, corticomotor excitability, repetitive peripheral nerve stimulation
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • bihemispheric transcranial direct stimulationDevice

    Also called repetitive peripheral stimulation

    tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.

    Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA).

Study groups in NCT04178395
Study groupRoleWhat they receive
real tDCS groupExperimentalPatients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric transcranial direct stimulation and repetitive peripheral stimulation for 5 consecutive days.
Receives: Device: bihemispheric transcranial direct stimulation
sham groupSham comparatorPatients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days.
Receives: Device: bihemispheric transcranial direct stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Upper limb Fugl-Meyer scale

    Motor assessment stroke-specific, performance-based impairment index, designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. Unit of measure 0-66 (higher scores reflect better outcome)

    Measured: one year

  2. Modified Ashworth scale

    Measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Unit of measure 0-4 (higher scores reflect increase spasticity)

    Measured: one year

  3. Resting motor threshold

    Corticomotor excitability measure is the lowest stimulator output at the optimal scalp site required to elicit a MEP of at least 50 μV. Unit of measure: % of maximal stimulator output.

    Measured: one year

  4. Contralateral and ipsilateral silent period

    Evaluates corticomotor excitability of each hemisphere and transcallosal contralateral's hemisphere influence. Transcranial magnetic stimulation is applied over the M1 area of each hemisphere while patients sustained a steady maximum tonic contraction of the muscle and ipsilateral and contralateral responses of both upper limbs are recorded. Unit of measure: miliseconds

    Measured: one year

  5. Motor evoked potentials

    Motor evoked potentials refers to the action potential elicited by noninvasive stimulation of the motor cortex through the scalp. Unit of measure: milivolts

    Measured: one year

  6. Somatosensory evoked potentials

    Somatosensory evoked potentials are the electrical activity of the brain that results from the stimulation of the somatosensory system, through electrical stimulation. Unit of measure: microvolts.

    Measured: one year

  7. Hmax/Mmax ratio

    H reflex, the electrical analogue of the spinal stretch reflex, allowed the investigators to study spinal circuitry excitability. The index Hmax/Mmax ratio was compared between the paretic and the non-paretic arm and is considered a neurophysiological measure of spasticity. Unit of measure: %

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2019
  2. Study start8 Apr 2011
  3. Primary completion31 Dec 2011
  4. Study completion9 Nov 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study was prospective, randomized, double-blind and placebo controlled. Twenty acute stroke patients (ischemic and haemorrhagic) with Upper limb Fugl-Meyer (ULFM) score\<19 were randomized in two parallel groups: one group received 5 consecutive daily sessions of anodal transcranial direct current stimulation (tDCS) over the affected hemisphere and cathodal over unaffected hemisphere combined with repetitive peripheral nerve stimulation (rPSN) and the other received sham tDCS associated to rPNS. Patients were examined before tDCS, 5 days and 3, 6 and 12 months after tDCS.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04178395
Sponsor's protocol ID
110932
Status last verified
Nov 2019
First submitted
21 Nov 2019
Last updated
26 Nov 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared as a original research article in a scientific journal.

Publications

  • Kandel M, Beis JM, Le Chapelain L, Guesdon H, Paysant J. Non-invasive cerebral stimulation for the upper limb rehabilitation after stroke: a review. Ann Phys Rehabil Med. 2012 Dec;55(9-10):657-80. doi: 10.1016/j.rehab.2012.09.001. Epub 2012 Sep 29. English, French.

    PubMed 23084320
  • Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3(Pt 3):633-9. doi: 10.1111/j.1469-7793.2000.t01-1-00633.x.

    PubMed 10990547
  • Sattler V, Acket B, Raposo N, Albucher JF, Thalamas C, Loubinoux I, Chollet F, Simonetta-Moreau M. Anodal tDCS Combined With Radial Nerve Stimulation Promotes Hand Motor Recovery in the Acute Phase After Ischemic Stroke. Neurorehabil Neural Repair. 2015 Sep;29(8):743-54. doi: 10.1177/1545968314565465. Epub 2015 Jan 7.

    PubMed 25567120
  • Rossi C, Sallustio F, Di Legge S, Stanzione P, Koch G. Transcranial direct current stimulation of the affected hemisphere does not accelerate recovery of acute stroke patients. Eur J Neurol. 2013 Jan;20(1):202-4. doi: 10.1111/j.1468-1331.2012.03703.x. Epub 2012 Mar 26.

    PubMed 22448901
  • Hesse S, Waldner A, Mehrholz J, Tomelleri C, Pohl M, Werner C. Combined transcranial direct current stimulation and robot-assisted arm training in subacute stroke patients: an exploratory, randomized multicenter trial. Neurorehabil Neural Repair. 2011 Nov-Dec;25(9):838-46. doi: 10.1177/1545968311413906. Epub 2011 Aug 8.

    PubMed 21825004
  • Rabadi MH, Aston CE. Effect of Transcranial Direct Current Stimulation on Severely Affected Arm-Hand Motor Function in Patients After an Acute Ischemic Stroke: A Pilot Randomized Control Trial. Am J Phys Med Rehabil. 2017 Oct;96(10 Suppl 1):S178-S184. doi: 10.1097/PHM.0000000000000823.

    PubMed 28837443

Questions about this trial

What is this clinical trial studying?

A study testing bihemispheric transcranial direct stimulation in people with Stroke and Acute Stroke, run by Sara Yagüe MD at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Upper limb Fugl-Meyer scale (time frame: one year). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04178395, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in